The application of Meta-analysis in the latest comprehensive treatment of breast cancer
- First Online:
- 26 Downloads
Meta-analysis is a kind of systematic review, which uses quantitative method to summarize the results. It is a comprehensive evaluation to the findings of previous studies with higher credibility. Recently, it is applied to all areas of scientific research, particularly in the integrated treatment of breast cancer. Currently, breast cancer is known one of the most common malignant tumors, and its incidence is increasing year by year. Therefore, more and more clinical doctors pay attention to the effect of comprehensive treatment for patients with breast cancer. This article mainly collects the results of comprehensive treatment of breast cancer, in which the method of Meta-analysis is applied. In addition, we discuss the latest progress in order to guide the clinical treatment.
Key wordsMeta-analysis breast cancer comprehensive treatment
Unable to display preview. Download preview PDF.
- 11.Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res, 2007, 13: 228–233.CrossRefPubMedGoogle Scholar
- 18.Fountzilas G, Dafni U, Gogas H, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol, 2008, 19: 853–860.CrossRefPubMedGoogle Scholar
- 20.Chiesa MD, Passalacqua R, Michiara M, et al. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial. Acta Biomed, 2007, 78: 204–209.PubMedGoogle Scholar
- 23.Guarneri V, Frassoldati A, Bruzzi P, et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer, 2008, 8: 453–456.CrossRefPubMedGoogle Scholar
- 29.Zhang WB, Wang B, Shi LC. The application of traditional Chinese medical in the modern breast cancer treatment. Chin J Integr Tradit West Med Intens Crit Care (Chinese), 2002, 1: 54–55.Google Scholar